Interv Akut Kardiol. 2014;13(4):190-194

Pretreatment with P2Y12 inhibitors for acute myocardial infarction

Ivo Varvařovský
Kardiologické centrum Agel, Pardubice

Clopidogrel treatment starting before transportation for primary PCI is better then in-hospital administration according to observational

studies. Prasugrel is most potent contemporary drug for STEMI treatment, but data for prehospital administration are insufficient. Prehospital

administration of ticagrelor is as effective as in-hospital treatment.

Keywords: pretreatment, acute myocardial infarction, prasugrel, ticagrelor

Published: December 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Pretreatment with P2Y12 inhibitors for acute myocardial infarction. Interv Akut Kardiol. 2014;13(4):190-194.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ISIS-2 Collaborative Group. Randomised trial of itravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; 2(8607): 349-360. Go to original source...
    2. Bosch XC, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev 2013; 11: CD002130.doi: 10.1002/14651858. Go to original source... Go to PubMed...
    3. Stone GW, Grines CL, Cox DA. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-966. Go to original source... Go to PubMed...
    4. Montalescot G, Borentain M, Payot L. Early versus late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292: 362-366. Go to original source... Go to PubMed...
    5. Steg G, James SK, Atar D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619. Go to original source... Go to PubMed...
    6. Van´t Hof AW, ten Berg JM, Heestermans T. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372: 537-546. Go to original source... Go to PubMed...
    7. Heestermans T, van´t Hof AW, ten Berg JM. The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis for the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J 2010; 160: 1079-1084. Go to original source... Go to PubMed...
    8. Moussa I, Oetgen M, Roubin G. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99: 2364-2366. Go to original source... Go to PubMed...
    9. Lansky AJ, Tsuchiya Y, Brener M. Comparison between ticlopidine and clopidogrel in patients undergoing coronary stenting in acute myocardial infarction: results from the CADILLAC trial. Catheter Cardiovasc Interv 2008; 72: 917-924. Go to original source... Go to PubMed...
    10. Wiviott SD, Braunwald E, McCabe CH. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-2015. Go to original source... Go to PubMed...
    11. Wiviott SD, Desai N, Murphy SA. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011; 108: 905-911. Go to original source... Go to PubMed...
    12. Montalescot G, Wiviott SD, Braunwald E. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-731. Go to original source... Go to PubMed...
    13. Wilcox R, Iqbal K, Costigan T. An analysis of TRITON-TIMI 38, based on the 12 month recomended length of therapy in the European label for prasugrel. Curr Med Res Opin 2014; 30: 2193-2205. Go to original source... Go to PubMed...
    14. Wallentin L, Becker RC, Budaj A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057. Go to original source... Go to PubMed...
    15. Steg PG, James S, Harrington RA. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention. Circulation 2010; 122: 2131-2141. Go to original source... Go to PubMed...
    16. Armstrong PW, Siha H, Fu Y. ST-elevation acute coronary syndromes in the PLATO trial: insights from the ECG substudy. Circulation 2012; 125: 514-521. Go to original source... Go to PubMed...
    17. Steinhubl SR, Berger PB, Mann JT. Early and sustained oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. JAMA 2002; 288: 2411-2420. Go to original source... Go to PubMed...
    18. Sabatine MS, Cannon CP, Gibson CM. Effect pf clopidogrel preatreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224-1232. Go to original source... Go to PubMed...
    19. Zeymer U, Arntz HR, Mark B. Efficacy and safety of a high loading dose of clopidogrel administered prehospitaly to improve percutaneous coronary intervention in acute myocardial infarction: the randomised CIPAMI trial. Clin Res Cardiol 2012; 101: 305-312. Go to original source... Go to PubMed...
    20. Ferreiro JL, Homs S, Berdejo J. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevelance of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. Thromb Haemost 2013; 110: 110-117. Go to original source... Go to PubMed...
    21. Beigel R, Feffer P, Rosenberg N. Antiplatelet effect of thienopyridine pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. Am J Cardiol 2013; 112: 1551-1556. Go to original source... Go to PubMed...
    22. Vlaar PJ, Svilaas T, Damman K. Impact of preatreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review. Circulation 2008; 118: 1828-1836. Go to original source... Go to PubMed...
    23. De Waha S, Eitel I, Desch S. Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac imaging in patients with ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2014; 3: 110-117. Go to original source... Go to PubMed...
    24. Fefer P, Hod H, Hammerman H. Usefulness of preatreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am J Cardiol 2009; 104: 514-518. Go to original source... Go to PubMed...
    25. Larson DM, Duval S, Sharkey SS. Clopidogrel preatreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. Am Heart J 2010: 160: 202-207. Go to original source... Go to PubMed...
    26. Dorler J, Edlinger M, Alber HF. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011; 32: 2954-2961. Go to original source... Go to PubMed...
    27. Koul S, Smith JG, Schersten F. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2011; 32: 2989-2997. Go to original source... Go to PubMed...
    28. Waite LH, Phan YL, Spinler SA. Cangrelor: a novel intravenous antiplatelet agent with questionable future. Pharmacotherapy 2014; Aug 13. doi: 10.1002/phar.1471. [Epub ahead of print. Go to original source... Go to PubMed...
    29. Parodi G, Valenti R, Bellandi B. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients. J Am Coll Cardiol 2013; 61: 1601-1606. Go to original source... Go to PubMed...
    30. Alexopoulos D, Xanthopoulou I, Gkizas V. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804. Go to original source... Go to PubMed...
    31. Parodi G, Bellandi B, Valenti R. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. Am Heart J 2014; 167: 909-914. Go to original source... Go to PubMed...
    32. Hibbert B, Maze R, Pourdjabbar A. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS One 2014; 9: e92078. Go to original source... Go to PubMed...
    33. Nührenberg TG, Trenk D, Leggewie S. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Platelets 2013; 24: 549-553. Go to original source... Go to PubMed...
    34. Lhermusier T, Lipinski MJ, Drenning D. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. J Interv Cardiol 2014; 27: 365-372. Go to original source... Go to PubMed...
    35. Diodati JG, Saucedo JF, Cardillo TE. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. Thromb Haemost 2014; 112: 311-322. Go to original source... Go to PubMed...
    36. Windecker S, Kolh P, Alfonso F. 2014 ECS/EACTS guidelines on myocardial revascularization. Euro Heart J 2014; doi: 10.1093/eurheartj/ehu278. Go to original source... Go to PubMed...
    37. Alexopoulos D, Makris G, Xanthopoulou I. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study. Circ Cardiovasc Interv 2014; 7: 233-239. Go to original source... Go to PubMed...
    38. Beigel R, Fefer P, Rosenberg N. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. Am J Cardiol 2013; 112: 1551-1556. Go to original source... Go to PubMed...
    39. Li Y, Tai B, Phua Q. Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. J Thromb Thrombolysis 2012; 34: 499-505. Go to original source... Go to PubMed...
    40. Armstrong PW, Siha H, Fu Y. ST-elevation acute coronary syndromes in the PLATO trial: insights from the ECG substudy. Circulation 2012; 125: 514-521. Go to original source... Go to PubMed...
    41. Montalescot G, van´t Hof AW, Lapostolle F. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.